Syndecan-1: A Novel Diagnostic and Therapeutic Target in Liver Diseases

Curr Drug Targets. 2023 Nov 7. doi: 10.2174/0113894501250057231102061624. Online ahead of print.ABSTRACTSyndecan-1 (SDC-1), known as a coreceptor of various growth factors or an integrin binding partner, regulates various cell behaviours. Under certain pathological conditions, SDC-1 is shed from the cell surface and plays a protective or pathogenic role in various diseases. In the liver, SDC-1 is highly expressed in hepatocytes, where it is localized on the basolateral surface. It is critical to the cellular and molecular functions of hepatocytes, including their attachment to hepatitis viruses. Previous studies have reported that SDC-1 may function as a novel and promising diagnostic and therapeutic marker for various liver diseases, such as drug-induced liver injury, liver fibrosis, and liver cancer. In this review, we summarize related research and highlight the mechanisms by which SDC-1 participates in the pathogenesis of liver diseases, as well as its potential diagnostic and therapeutic applications. This review is expected to lay the foundation for further therapeutic strategies to target SDC-1 in liver diseases.PMID:37957867 | DOI:10.2174/0113894501250057231102061624
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research